What does the application actually ask about Crohn's or colitis?
Simplified issue life insurance asks a set of yes or no health questions organized by category. IBD, including Crohn's disease and ulcerative colitis, is not captured in the standard health sections that most people worry about. It appears in a separate pass of the question set that assesses whether the condition creates any significant ongoing functional restriction. For most people managing IBD, even on active treatment, it does not.
The practical outcome: both term and permanent coverage are typically available at rates typical for simplified issue coverage, with amounts that can reach $500,000 or more depending on age and carrier. There is no deferral, no waiting period, and no lower coverage ceiling applied by the IBD diagnosis itself. This puts IBD in a more favourable position than most readers expect, and than most chronic conditions produce.
Crohn's disease and ulcerative colitis are among the most favourably assessed chronic conditions in the Canadian simplified issue market. Most applicants with IBD, including those on active biologic therapy, have access to the full range of simplified issue products at standard rates. A licensed advisor can confirm the specific outcome for a given situation and identify the most favourable carriers.
How do biologics or immunosuppressants affect your application?
This is where most people expect the conversation to turn against them. Many Canadians with moderate to severe IBD are on biologic therapies including Humira, Remicade, Entyvio, and Stelara, or immunosuppressants like azathioprine. These are powerful medications, and the assumption that they will trigger a negative underwriting assessment is understandable.
In the simplified issue market, they don't. The IBD question set does not ask about medication type. Biologics are not an independent trigger. What underwriters can see is that a treatment plan is in place and that the condition is being actively managed. Consistent, long-term biologic use at a stable dose communicates exactly what underwriters want to see: a condition that is under control.
A recent medication change is the one area worth flagging. A new biologic prescription, a switch between biologics, or a dosage adjustment within the last 12 months may be captured by the medication-change question that most simplified issue applications include. That question typically has a modest effect on the outcome relative to the IBD question itself, but a licensed advisor should know about it before an application goes in so the right carrier and timing are selected.
If you switched biologics in the last year because a biosimilar was mandated by your provincial drug plan, that counts as a medication change for application purposes even if the clinical outcome was identical. It is worth flagging this to a licensed advisor before applying, not because it prevents coverage, but because the right carrier and timing matter in that window.
Which complications actually shift what's available?
IBD on its own is not a barrier. Certain complications that develop alongside IBD can shift the picture, and these are worth knowing before an application is submitted.
Liver involvement. Primary sclerosing cholangitis, a bile duct condition that occurs more frequently in people with ulcerative colitis, is the most consequential IBD complication for life insurance purposes. Any liver disease diagnosis, including PSC, is assessed under the liver question independently of the IBD. A liver disease diagnosis shifts the outcome to a permanent-only structure with a waiting period and lower coverage amounts. If liver involvement has ever been diagnosed, that is the binding constraint, not the IBD.
GI cancer. A history of colon cancer or other GI malignancy is assessed under the cancer question set. Depending on when it was diagnosed and treated, the cancer timing framework governs. The IBD is background context. The cancer survivor article on this site covers how timing affects that outcome in detail.
Recent hospitalization. A hospitalization for an IBD flare within the last 60 days shifts the outcome temporarily to a restricted structure. Once that window clears, the standard IBD outcome applies again. The hospitalization article explains how this window works across conditions.
For applicants without any of these complications, the IBD picture is clean and the coverage available is as broad as simplified issue gets.
Is Crohn's disease assessed differently from ulcerative colitis?
For simplified issue purposes, no. Both Crohn's disease and ulcerative colitis sit within the same IBD category and produce the same eligibility outcome. The clinical distinction, that Crohn's can affect any part of the digestive tract while colitis is limited to the colon, is not a factor in the simplified issue question set. Whether the diagnosis says Crohn's disease, ulcerative colitis, or indeterminate colitis, the outcome is the same.
In the fully underwritten market, the type and extent of disease can factor into a more detailed assessment. But for the simplified issue market that most Canadians with IBD are accessing, the type is irrelevant to the outcome.
What to Bring to the Conversation
Before speaking with a licensed advisor, know your current medications and how long they have been stable. Know whether any hospitalizations for IBD have occurred in the last 60 days. Know whether any liver conditions or GI cancers have ever been diagnosed. That picture is what determines the right carrier and product.
Know the monthly premium that is genuinely comfortable to sustain. Know the obligations a death would leave behind: a mortgage, income a spouse depends on, final expenses. Coverage amount follows from that picture.
Most Canadians with Crohn's or colitis are in a considerably stronger position than they expected before this conversation started. The IBD diagnosis is not the obstacle it looks like from the outside.
This article is for educational purposes only and does not constitute insurance advice. Eligibility, premiums, and coverage terms vary by individual health profile and insurer. Speak with a licensed Canadian insurance advisor before making any coverage decision. Reviewed by a licensed Canadian insurance professional.